Skip to main content

Table 3 Co-morbidities in CS+/CS- and FM+/FM- patient

From: Prevalence of fibromyalgia in France: a multi-step study research combining national screening and clinical confirmation: The DEFI study (Determination of Epidemiology of FIbromyalgia)

  Patients with potential or established fibromyalgia Patients attending consultation with rheumatologist
  CS+ CS- FM+ FM-
Number of patients 96 49 20 76
Co-morbidities (%)     
Long-term fatigue [95% CI] 76.3
[67.7; 85.0]
68.9
[55.4; 82.4]
85.0
[69.4; 100.0]
74.0
[63.9; 84.0]
Cramp type digestive disorders [95% CI] 54.4
[44.2; 64.5]
52.4
[37.3; 67.5]
79.0
[60.6; 97.3]
48.0
[36.5; 59.4]
Headaches [95% CI] 53.4
[43.0; 63.8]
41.0
[25.6;56.5]
66.7
[44.9; 88.4]
50.0
[38.3; 61.7]
Anxiety 95% CI] 75.8
[67.2; 84.4]
74.4
[61.4; 87.5]
84.2
[67.8; 100.0]
73.7
[63.8; 83.6]
Depression [95% CI] 39.3
[29.2; 49.5]
40.5
[24.7;56.4]
47.4
[24.9; 69.8]
37.1
[25.8;48.5]
Rheumatoid arthritis [95% CI] 7.4
[2.1; 12.6]
19.2
[7.9; 30.4]
15.0
[0.0; 30.7]
5.3
[0.3; 10.4]
Systemic lupus erythematosus [95% CI] 1.1
[0.0; 3.2]
0.0
[0.0; 0.0]
0.0
[0.0; 0.0]
1.4
[0.0; 4.0]
  1. CS+: patients attending consultation with rheumatologist and completing patient questionnaire; CS-: patients completing patient questionnaire without attending consultation with rheumatologist; FM+: = confirmed diagnosis of fibromyalgia by a rheumatologist; FM-: = non-confirmed diagnosis of fibromyalgia by a rheumatologist
\